Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed to treat type 2 diabetes. One unexpected side effect of these drugs is weight loss.

In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...

Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

Taiwan: A recent cohort study has highlighted the potential benefits of combining glucagon-like peptide-1 receptor agonists ...

Background: Glucagon-like peptide-1(7–36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility. Aims: To assess the effects of ...